What is the difference between GHRH analogs and ghrelin mimetics as growth hormone secretagogues?

GHRH analogs (such as Tesamorelin and CJC-1295) act at the GHRH receptor on pituitary somatotrophs, mimicking the endogenous GHRH pulse that drives GH secretion. Ghrelin mimetics (such as Ipamorelin and GHRP-6) act at the GHSR-1a receptor, a different pathway that also promotes GH release and can synergize with GHRH stimulation. When a GHRH analog and a ghrelin mimetic are used together in research, their combined effect on GH secretion can be substantially greater than either alone due to different and complementary receptor mechanisms.

How are growth hormone secretagogues studied in preclinical models?

Preclinical GHS research typically uses rodent or primate models with cannulated access to the jugular vein or carotid artery for serial blood sampling. GH levels are measured by radioimmunoassay or ELISA at frequent intervals (every 5 to 15 minutes) to capture pulsatile GH release patterns. Longer-term studies measure downstream IGF-1 levels, body composition changes by DEXA, and metabolic parameters. GH-deficient or aged animal models are often used to create a baseline condition against which GHS compound effects can be measured.

Mechanism

Growth Hormone Secretagogue

A compound that stimulates the release of growth hormone from pituitary cells through receptor-mediated mechanisms.

Definition

A growth hormone secretagogue (GHS) is any compound that stimulates the secretion of growth hormone (GH) from somatotroph cells in the anterior pituitary gland. This stimulation can occur through multiple receptor-mediated mechanisms, including agonism at the growth hormone-releasing hormone receptor (GHRHR), agonism at the ghrelin receptor (GHSR-1a), or a combination of both. GHS compounds are studied for their ability to augment or normalize pulsatile GH release patterns in preclinical models of GH deficiency, aging, or metabolic dysfunction. The class includes both peptide-based compounds (such as GHRH analogs and ghrelin mimetics) and non-peptide small molecules.

Research Context

Growth hormone secretagogues represent one of the most extensively researched peptide compound classes in preclinical endocrinology. Research models examining GHS compounds measure GH pulse amplitude, pulsatile frequency, downstream IGF-1 levels, and longer-term metabolic outcomes in rodent and primate models. Compounds such as Tesamorelin (a GHRH analog) and CJC-1295/Ipamorelin (combined GHRH/ghrelin receptor agonists) are the primary GHS peptides studied for growth hormone axis modulation in preclinical metabolic research.

Relevant Compounds

This term applies to the following research compound hubs.

tesamorelinView hub →cjc ipaView hub →aod 9604View hub →

Frequently Asked Questions

Explore the Research Library

Compound comparisons, research use cases, study indexes, and more. A complete reference for research-grade peptide science.

Research Library →All Glossary Terms ↑

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research